The anti-programmed cell death protein 1 (PD-1) antibody cemiplimab has shown remarkable efficacy in the treatment of unresectable or metastatic cutaneous squamous cell carcinoma (CSCC) (1). This evidence concerns the gene PDCD1 and skin squamous cell carcinoma.